L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

Ilaria Marrocco; Suvendu Giri; Arturo Simoni-Nieves; Nitin Gupta; Anna Rudnitsky; Yuya Haga; Donatella Romaniello; Arunachalam Sekar; Mirie Zerbib; Roni Oren; Moshit Lindzen; Damon Fard; Yasuo Tsutsumi; Mattia Lauriola; Luca Tamagnone; Yosef Yarden

doi:10.1016/j.xcrm.2023.101142

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

Ilaria Marrocco, Suvendu Giri, Arturo Simoni-Nieves, Nitin Gupta, Anna Rudnitsky, Yuya Haga, Donatella Romaniello, Arunachalam Sekar, Mirie Zerbib, Roni Oren, Moshit Lindzen, Damon Fard, Yasuo Tsutsumi, Mattia Lauriola, Luca Tamagnone, Yosef Yarden^*

^*Corresponding author

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	101142-101142
Number of pages	1
Journal	Cell Reports Medicine
Volume	4
DOIs	https://doi.org/10.1016/j.xcrm.2023.101142
Publication status	Published - 2023

Keywords

EGFR
NSCLC
adaptive mutability
cetuximab
kinase inhibitors
lung cancer
monoclonal antibody
osimertinib
receptor tyrosine kinases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.xcrm.2023.101142

Cite this

Marrocco, I., Giri, S., Simoni-Nieves, A., Gupta, N., Rudnitsky, A., Haga, Y., Romaniello, D., Sekar, A., Zerbib, M., Oren, R., Lindzen, M., Fard, D., Tsutsumi, Y., Lauriola, M., Tamagnone, L., & Yarden, Y. (2023). L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell Reports Medicine, 4, 101142-101142. https://doi.org/10.1016/j.xcrm.2023.101142

@article{ecfe7f44606242cba94622918d864648,

title = "L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab",

keywords = "EGFR, NSCLC, adaptive mutability, cetuximab, kinase inhibitors, lung cancer, monoclonal antibody, osimertinib, receptor tyrosine kinases, EGFR, NSCLC, adaptive mutability, cetuximab, kinase inhibitors, lung cancer, monoclonal antibody, osimertinib, receptor tyrosine kinases",

author = "Ilaria Marrocco and Suvendu Giri and Arturo Simoni-Nieves and Nitin Gupta and Anna Rudnitsky and Yuya Haga and Donatella Romaniello and Arunachalam Sekar and Mirie Zerbib and Roni Oren and Moshit Lindzen and Damon Fard and Yasuo Tsutsumi and Mattia Lauriola and Luca Tamagnone and Yosef Yarden",

year = "2023",

doi = "10.1016/j.xcrm.2023.101142",

language = "English",

volume = "4",

pages = "101142--101142",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

}

Marrocco, I, Giri, S, Simoni-Nieves, A, Gupta, N, Rudnitsky, A, Haga, Y, Romaniello, D, Sekar, A, Zerbib, M, Oren, R, Lindzen, M, Fard, D, Tsutsumi, Y, Lauriola, M, Tamagnone, L & Yarden, Y 2023, 'L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab', Cell Reports Medicine, vol. 4, pp. 101142-101142. https://doi.org/10.1016/j.xcrm.2023.101142

TY - JOUR

T1 - L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

AU - Marrocco, Ilaria

AU - Giri, Suvendu

AU - Simoni-Nieves, Arturo

AU - Gupta, Nitin

AU - Rudnitsky, Anna

AU - Haga, Yuya

AU - Romaniello, Donatella

AU - Sekar, Arunachalam

AU - Zerbib, Mirie

AU - Oren, Roni

AU - Lindzen, Moshit

AU - Fard, Damon

AU - Tsutsumi, Yasuo

AU - Lauriola, Mattia

AU - Tamagnone, Luca

AU - Yarden, Yosef

PY - 2023

Y1 - 2023

KW - EGFR

KW - NSCLC

KW - adaptive mutability

KW - cetuximab

KW - kinase inhibitors

KW - lung cancer

KW - monoclonal antibody

KW - osimertinib

KW - receptor tyrosine kinases

KW - EGFR

KW - NSCLC

KW - adaptive mutability

KW - cetuximab

KW - kinase inhibitors

KW - lung cancer

KW - monoclonal antibody

KW - osimertinib

KW - receptor tyrosine kinases

UR - http://hdl.handle.net/10807/247494

U2 - 10.1016/j.xcrm.2023.101142

DO - 10.1016/j.xcrm.2023.101142

M3 - Article

SN - 2666-3791

VL - 4

SP - 101142

EP - 101142

JO - Cell Reports Medicine

JF - Cell Reports Medicine

ER -

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

Keywords

UN SDGs

Access to Document

Other files and links

Cite this